Prion protein lowering is a disease-modifying therapy across prion disease stages, strains and endpoints.

To evaluate astroglial proliferation, we imaged N = 36 Tg( Gfap -luc) RML prion-infected and N = 14 uninfected mice by BLI every 7–11 days, and pre-specified that a single 500 μg dose of ASO 1, 2 or 3 would be administered after two consecutive imaging sessions showed a nominally significant ( P < 0.05 by a two-sided Kolmogorov–Smirnov test) difference in BLI between infected and uninfected mice.

also in 7,732 other papers